Today: Today, Eli Lilly and’s (LLY) “Overweight” Rating Reaffirm at JPMorgan Chase & Co.

Today, Eli Lilly and’s (LLY) “Overweight” Rating Reaffirm at JPMorgan Chase & Co.

Eli Lilly and Co. (NYSE:LLY)‘s stock had its “overweight” rating reissued by JPMorgan Chase & Co. in a research report issued to clients and investors on Saturday. They currently have a $384.00 target price on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 455.56% from the company’s current price.

LLY has been the topic of several other reports. BMO Capital Markets restated a “buy” rating and set a $94.00 price target on shares of Eli Lilly and in a report on Monday, October 3rd. Jefferies Group restated a “buy” rating and set a $100.00 price target (down from $105.00) on shares of Eli Lilly and in a report on Friday, October 28th. Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and in a report on Tuesday, November 8th. Leerink Swann restated a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a report on Sunday, October 9th. Finally, Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $108.95.

Shares of Eli Lilly and (NYSE:LLY) opened at 69.12 on Friday. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $88.16. The company has a market capitalization of $73.11 billion, a PE ratio of 30.07 and a beta of 0.28. The company’s 50-day moving average price is $76.69 and its 200-day moving average price is $77.92.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. The firm had revenue of $5.19 billion for the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.89 earnings per share. On average, equities analysts expect that Eli Lilly and will post $3.55 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be issued a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 annualized dividend and a dividend yield of 2.95%. Eli Lilly and’s dividend payout ratio is 88.70%.

In other news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now owns 94,319 shares in the company, valued at $7,674,737.03. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. increased its stake in shares of Eli Lilly and by 0.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,305 shares of the company’s stock valued at $260,000 after buying an additional 31 shares during the period. Chevy Chase Trust Holdings Inc. increased its stake in shares of Eli Lilly and by 1.1% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 836,508 shares of the company’s stock valued at $65,876,000 after buying an additional 8,987 shares during the period. Exxonmobil Investment Management Inc. TX increased its stake in shares of Eli Lilly and by 6.1% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 251,441 shares of the company’s stock valued at $19,801,000 after buying an additional 14,451 shares during the period. DNB Asset Management AS increased its stake in shares of Eli Lilly and by 14.8% in the second quarter. DNB Asset Management AS now owns 235,250 shares of the company’s stock valued at $18,526,000 after buying an additional 30,400 shares during the period. Finally, Washington Trust Bank increased its stake in shares of Eli Lilly and by 7.7% in the second quarter. Washington Trust Bank now owns 7,118 shares of the company’s stock valued at $561,000 after buying an additional 509 shares during the period. Hedge funds and other institutional investors own 75.11% of the company’s stock.

Eli Lilly and Company Profile

Related posts

Leave a Comment